These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20957429)

  • 1. Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women.
    Comen E; Balistreri L; Gönen M; Dutra-Clarke A; Fazio M; Vijai J; Stadler Z; Kauff N; Kirchhoff T; Hudis C; Offit K; Robson M
    Breast Cancer Res Treat; 2011 Jun; 127(2):479-87. PubMed ID: 20957429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of Risk Prediction Models for Breast Cancer and
    Kenan ES; Friger M; Shochat-Bigon D; Schayek H; Bernstein-Molho R; Friedman E
    Anticancer Res; 2018 Aug; 38(8):4557-4563. PubMed ID: 30061222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk.
    Quante AS; Whittemore AS; Shriver T; Hopper JL; Strauch K; Terry MB
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25956172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Finch A; Poll A; Horsman D; Kim-Sing C; Scott J; Royer R; Sun P; Narod SA
    Br J Cancer; 2009 Jan; 100(2):421-5. PubMed ID: 19088722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers.
    Huo Z; Giger ML; Olopade OI; Wolverton DE; Weber BL; Metz CE; Zhong W; Cummings SA
    Radiology; 2002 Nov; 225(2):519-26. PubMed ID: 12409590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas.
    Vos S; Elias SG; van der Groep P; Smolders YH; van Gils CH; van Diest PJ
    Am J Surg Pathol; 2018 Sep; 42(9):1262-1272. PubMed ID: 29979200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.
    Antoniou AC; Beesley J; McGuffog L; Sinilnikova OM; Healey S; Neuhausen SL; Ding YC; Rebbeck TR; Weitzel JN; Lynch HT; Isaacs C; Ganz PA; Tomlinson G; Olopade OI; Couch FJ; Wang X; Lindor NM; Pankratz VS; Radice P; Manoukian S; Peissel B; Zaffaroni D; Barile M; Viel A; Allavena A; Dall'Olio V; Peterlongo P; Szabo CI; Zikan M; Claes K; Poppe B; Foretova L; Mai PL; Greene MH; Rennert G; Lejbkowicz F; Glendon G; Ozcelik H; Andrulis IL; ; Thomassen M; Gerdes AM; Sunde L; Cruger D; Birk Jensen U; Caligo M; Friedman E; Kaufman B; Laitman Y; Milgrom R; Dubrovsky M; Cohen S; Borg A; Jernström H; Lindblom A; Rantala J; Stenmark-Askmalm M; Melin B; ; Nathanson K; Domchek S; Jakubowska A; Lubinski J; Huzarski T; Osorio A; Lasa A; Durán M; Tejada MI; Godino J; Benitez J; Hamann U; Kriege M; Hoogerbrugge N; van der Luijt RB; van Asperen CJ; Devilee P; Meijers-Heijboer EJ; Blok MJ; Aalfs CM; Hogervorst F; Rookus M; ; Cook M; Oliver C; Frost D; Conroy D; Evans DG; Lalloo F; Pichert G; Davidson R; Cole T; Cook J; Paterson J; Hodgson S; Morrison PJ; Porteous ME; Walker L; Kennedy MJ; Dorkins H; Peock S; ; Godwin AK; Stoppa-Lyonnet D; de Pauw A; Mazoyer S; Bonadona V; Lasset C; Dreyfus H; Leroux D; Hardouin A; Berthet P; Faivre L; ; Loustalot C; Noguchi T; Sobol H; Rouleau E; Nogues C; Frénay M; Vénat-Bouvet L; ; Hopper JL; Daly MB; Terry MB; John EM; Buys SS; Yassin Y; Miron A; Goldgar D; ; Singer CF; Dressler AC; Gschwantler-Kaulich D; Pfeiler G; Hansen TV; Jønson L; Agnarsson BA; Kirchhoff T; Offit K; Devlin V; Dutra-Clarke A; Piedmonte M; Rodriguez GC; Wakeley K; Boggess JF; Basil J; Schwartz PE; Blank SV; Toland AE; Montagna M; Casella C; Imyanitov E; Tihomirova L; Blanco I; Lazaro C; Ramus SJ; Sucheston L; Karlan BY; Gross J; Schmutzler R; Wappenschmidt B; Engel C; Meindl A; Lochmann M; Arnold N; Heidemann S; Varon-Mateeva R; Niederacher D; Sutter C; Deissler H; Gadzicki D; Preisler-Adams S; Kast K; Schönbuchner I; Caldes T; de la Hoya M; Aittomäki K; Nevanlinna H; Simard J; Spurdle AB; Holland H; Chen X; ; Platte R; Chenevix-Trench G; Easton DF;
    Cancer Res; 2010 Dec; 70(23):9742-54. PubMed ID: 21118973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer.
    Metcalfe KA; Lubinski J; Gronwald J; Huzarski T; McCuaig J; Lynch HT; Karlan B; Foulkes WD; Singer CF; Neuhausen SL; Senter L; Eisen A; Sun P; Narod SA;
    Clin Genet; 2018 May; 93(5):1063-1068. PubMed ID: 29206279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?
    Semple J; Metcalfe KA; Lubinski J; Huzarski T; Gronwald J; Armel S; Lynch HT; Karlan B; Foulkes W; Singer CF; Neuhausen SL; Eng C; Iqbal J; Narod SA;
    Breast Cancer Res Treat; 2015 Nov; 154(1):163-9. PubMed ID: 26467043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer risk associated with BRCA1/2 variants in the Pakistani population.
    Abbas S; Siddique A; Shahid N; Khan RT; Fatima W
    Breast Cancer; 2019 May; 26(3):365-372. PubMed ID: 30430339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.
    Welsh JL; Hoskin TL; Day CN; Thomas AS; Cogswell JA; Couch FJ; Boughey JC
    Ann Surg Oncol; 2017 Oct; 24(10):3067-3072. PubMed ID: 28766224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
    Plevova P; Cerna D; Balcar A; Foretova L; Zapletalova J; Silhanova E; Curik R; Dvorackova J
    Neoplasma; 2010; 57(4):325-32. PubMed ID: 20429623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection.
    Ibrahim SS; Hafez EE; Hashishe MM
    J Exp Clin Cancer Res; 2010 Jun; 29(1):82. PubMed ID: 20579331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.
    Basu NN; Ingham S; Hodson J; Lalloo F; Bulman M; Howell A; Evans DG
    Fam Cancer; 2015 Dec; 14(4):531-8. PubMed ID: 26239694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel.
    Bernstein-Molho R; Laitman Y; Schayek H; Reish O; Lotan S; Haim S; Zidan J; Friedman E
    Breast Cancer Res Treat; 2018 Feb; 167(3):697-702. PubMed ID: 29086229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
    Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
    Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.
    Hadar T; Mor P; Amit G; Lieberman S; Gekhtman D; Rabinovitch R; Levy-Lahad E
    JAMA Oncol; 2020 Sep; 6(9):1460-1463. PubMed ID: 32644100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.